Search

Ipsen SA.

Suletud

SektorRahandus

121.3 2.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

118.5

Max

121.8

Põhinäitajad

By Trading Economics

Sissetulek

220M

334M

Müük

-2.9M

1.8B

P/E

Sektori keskmine

21.173

27.91

Dividenditootlus

1.22

Kasumimarginaal

18.354

Töötajad

5,358

EBITDA

-73M

637M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+20.42% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.22%

4.01%

Turustatistika

By TradingEconomics

Turukapital

111M

9.4B

Eelmine avamishind

119.2

Eelmine sulgemishind

121.3

Uudiste sentiment

By Acuity

34%

66%

113 / 528 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Ipsen SA. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Ipsen SA. Prognoos

Hinnasiht

By TipRanks

20.42% tõus

12 kuu keskmine prognoos

Keskmine 136.2 EUR  20.42%

Kõrge 148 EUR

Madal 120 EUR

Põhineb 5 Wall Streeti analüütiku instrumendi Ipsen SA. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

3

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

99.85 / 104Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

113 / 528 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat